The role of mTOR signaling in Alzheimer disease

Frontiers in Bioscience - Scholar

Volumn 4 S, Issue 3, 2012, Pages 941-952

  Oddo, Salvatore ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Abeta; AD; Alzheimer's disease; Autophagy; Learning and memory; mTOR; Plaques; PS1; Rapamycin; Review; Tangles; Tau

Indexed keywords

AMYLOID BETA PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; TAU PROTEIN; TARGET OF RAPAMYCIN KINASE;

ALZHEIMER DISEASE; ARTICLE; AUTOPHAGY; HUMAN; LEARNING; MACROAUTOPHAGY; MEMORY; NERVE DEGENERATION; NONHUMAN; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM; REVIEW;

MAMMALIA;

ALZHEIMER DISEASE; ANIMALS; HUMANS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84869413374     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s310     Document Type: Article

References (122)

1. 2010 Alzheimer's disease facts and figures. Alzheimers Dement, 6, 158-94 (2010)
2. C. P. Ferri, M. Prince, C. Brayne, H. Brodaty, L. Fratiglioni, M. Ganguli, K. Hall, K. Hasegawa, H. Hendrie, Y. Huang, A. Jorm, C. Mathers, P. R. Menezes, E. Rimmer and M. Scazufca: Global prevalence of dementia: a Delphi consensus study. Lancet, 366, 2112-7 (2005) (Pubitemid 41797645)
3. D. Hirtz, D. J. Thurman, K. Gwinn-Hardy, M. Mohamed, A. R. Chaudhuri and R. Zalutsky: How common are the "common" neurologic disorders? Neurology, 68, 326-37 (2007) (Pubitemid 46188246)
4. H. W. Querfurth and F. M. LaFerla: Alzheimer's disease. N Engl J Med, 362, 329-44 (2010)
5. D. J. Selkoe: Soluble oligomers of the amyloid betaprotein impair synaptic plasticity and behavior. Behav Brain Res, 192, 106-13 (2008)
6. A. Caccamo, M. A. Maldonado, A. F. Bokov, S. Majumder and S. Oddo: CBP gene transfer increases BDNF levels and ameliorates learning and memory deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A, 107, 22687-92 (2010)
7. J. J. Palop and L. Mucke: Amyloid-beta-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nat Neurosci, 13, 812-8 (2010)
8. Q. L. Ma, M. E. Harris-White, O. J. Ubeda, M. Simmons, W. Beech, G. P. Lim, B. Teter, S. A. Frautschy and G. M. Cole: Evidence of Abeta-and transgenedependent defects in ERK-CREB signaling in Alzheimer's models. J Neurochem, 103, 1594-607 (2007) (Pubitemid 47631821)
9. J. J. Palop, J. Chin, N. Bien-Ly, C. Massaro, B. Z. Yeung, G. Q. Yu and L. Mucke: Vulnerability of dentate granule cells to disruption of arc expression in human amyloid precursor protein transgenic mice. J Neurosci, 25, 9686-93 (2005) (Pubitemid 41510909)
10. J. J. Palop, B. Jones, L. Kekonius, J. Chin, G. Q. Yu, J. Raber, E. Masliah and L. Mucke: Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc Natl Acad Sci U S A, 100, 9572-7 (2003) (Pubitemid 37033969)
11. R. Loewith, E. Jacinto, S. Wullschleger, A. Lorberg, J. L. Crespo, D. Bonenfant, W. Oppliger, P. Jenoe and M. N. Hall: Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell, 10, 457-68 (2002) (Pubitemid 35284167)
12. S. Wullschleger, R. Loewith and M. N. Hall: TOR signaling in growth and metabolism. Cell, 124, 471-84 (2006) (Pubitemid 43199434)
13. Z. D. Sharp and R. Strong: The role of mTOR signaling in controlling mammalian life span: what a fungicide teaches us about longevity. J Gerontol A Biol Sci Med Sci, 65, 580-9 (2010)
14. M. Kaeberlein, R. W. Powers, 3rd. K. K. Steffen, E. A. Westman, D. Hu, N. Dang, E. O. Kerr, K. T. Kirkland, S. Fields and B. K. Kennedy: Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science, 310, 1193-6 (2005) (Pubitemid 41681747)
15. R. W. Powers, 3rd. M. Kaeberlein, S. D. Caldwell, B. K. Kennedy and S. Fields: Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev, 20, 174-84 (2006) (Pubitemid 43112936)
16. K. Jia, D. Chen and D. L. Riddle: The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span. Development, 131, 3897-906 (2004) (Pubitemid 39232150)
17. P. Kapahi, B. M. Zid, T. Harper, D. Koslover, V. Sapin and S. Benzer: Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr Biol, 14, 885-90 (2004) (Pubitemid 38800910)
18. T. Vellai, K. Takacs-Vellai, Y. Zhang, A. L. Kovacs, L. Orosz and F. Muller: Genetics: influence of TOR kinase on lifespan in C. elegans. Nature, 426, 620 (2003) (Pubitemid 38009359)
19. D. E. Harrison, R. Strong, Z. D. Sharp, J. F. Nelson, C. M. Astle, K. Flurkey, N. L. Nadon, J. E. Wilkinson, K. Frenkel, C. S. Carter, M. Pahor, M. A. Javors, E. Fernandez and R. A. Miller: Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature, 460, 392-5 (2009)
20. C. Selman, J. M. Tullet, D. Wieser, E. Irvine, S. J. Lingard, A. I. Choudhury, M. Claret, H. Al-Qassab, D. Carmignac, F. Ramadani, A. Woods, I. C. Robinson, E. Schuster, R. L. Batterham, S. C. Kozma, G. Thomas, D. Carling, K. Okkenhaug, J. M. Thornton, L. Partridge, D. Gems and D. J. Withers: Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science, 326, 140-4 (2009)
21. W. L. An, R. F. Cowburn, L. Li, H. Braak, I. Alafuzoff, K. Iqbal, I. G. Iqbal, B. Winblad and J. J. Pei: Upregulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer's disease. Am J Pathol, 163, 591-607 (2003) (Pubitemid 36909421)
22. R. C. Chang, A. K. Wong, H. K. Ng and J. Hugon: Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal degeneration in Alzheimer's disease. Neuroreport, 13, 2429-32 (2002) (Pubitemid 36143538)
23. R. J. Griffin, A. Moloney, M. Kelliher, J. A. Johnston, R. Ravid, P. Dockery, R. O'Connor and C. O'Neill: Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J Neurochem, 93, 105-17 (2005) (Pubitemid 40463520)
24. R. Onuki, Y. Bando, E. Suyama, T. Katayama, H. Kawasaki, T. Baba, M. Tohyama and K. Taira: An RNAdependent protein kinase is involved in tunicamycininduced apoptosis and Alzheimer's disease. Embo J, 23, 959-68 (2004) (Pubitemid 38418762)
25. A. L. Peel and D. E. Bredesen: Activation of the cell stress kinase PKR in Alzheimer's disease and human amyloid precursor protein transgenic mice. Neurobiol Dis, 14, 52-62 (2003) (Pubitemid 37103179)
26. J. J. Pei, C. Bjorkdahl, H. Zhang, X. Zhou and B. Winblad: p70 S6 kinase and tau in Alzheimer's disease. J Alzheimers Dis, 14, 385-92 (2008)
27. J. J. Pei and J. Hugon: mTOR-dependent signalling in Alzheimer's disease. J Cell Mol Med, 12, 2525-32 (2008)
28. X. Li, W. L. An, I. Alafuzoff, H. Soininen, B. Winblad and J. J. Pei: Phosphorylated eukaryotic translation factor 4E is elevated in Alzheimer brain. Neuroreport, 15, 2237-40 (2004) (Pubitemid 39392247)
29. X. Li, I. Alafuzoff, H. Soininen, B. Winblad and J. J. Pei: Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J, 272, 4211-20 (2005) (Pubitemid 41160927)
30. D. Martin, M. Salinas, R. Lopez-Valdaliso, E. Serrano, M. Recuero and A. Cuadrado: Effect of the Alzheimer amyloid fragment Abeta (25-35) on Akt/PKB kinase and survival of PC12 cells. J Neurochem, 78, 1000-8 (2001) (Pubitemid 32823149)
31. E. Vander Haar, S. I. Lee, S. Bandhakavi, T. J. Griffin and D. H. Kim: Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol, 9, 316-23 (2007) (Pubitemid 46344611)
32. S. Ito, K. Kimura, M. Haneda, Y. Ishida, M. Sawada and K. Isobe: Induction of matrix metalloproteinases (MMP3, MMP12 and MMP13) expression in the microglia by amyloid-beta stimulation via the PI3K/Akt pathway. Exp Gerontol, 42, 532-7 (2007) (Pubitemid 46756086)
33. S. Ito, M. Sawada, M. Haneda, Y. Ishida and K. Isobe: Amyloid-beta peptides induce several chemokine mRNA expressions in the primary microglia and Ra2 cell line via the PI3K/Akt and/or ERK pathway. Neurosci Res, 56, 294-9 (2006) (Pubitemid 44574518)
34. F. Zhang, Z. M. Beharry, T. E. Harris, M. B. Lilly, C. D. Smith, S. Mahajan and A. S. Kraft: PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biol Ther, 8, 846-53 (2009)
35. K. Bhaskar, M. Miller, A. Chludzinski, K. Herrup, M. Zagorski and B. T. Lamb: The PI3K-Akt-mTOR pathway regulates Abeta oligomer induced neuronal cell cycle events. Mol Neurodegener, 4, 14 (2009)
36. C. Lafay-Chebassier, M. Paccalin, G. Page, S. Barc-Pain, M. C. Perault-Pochat, R. Gil, L. Pradier and J. Hugon: mTOR/p70S6k signalling alteration by Abeta exposure as well as in APP-PS1 transgenic models and in patients with Alzheimer's disease. J Neurochem, 94, 215-25 (2005) (Pubitemid 40911407)
37. E. H. Koo and S. L. Squazzo: Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J Biol Chem, 269, 17386-9 (1994) (Pubitemid 24218009)
38. J. P. Cleary, D. M. Walsh, J. J. Hofmeister, G. M. Shankar, M. A. Kuskowski, D. J. Selkoe and K. H. Ashe: Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci, 8, 79-84 (2005) (Pubitemid 41236735)
39. M. B. Podlisny, B. L. Ostaszewski, S. L. Squazzo, E. H. Koo, R. E. Rydell, D. B. Teplow and D. J. Selkoe: Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem, 270, 9564-70 (1995)
40. D. M. Walsh, I. Klyubin, J. V. Fadeeva, W. K. Cullen, R. Anwyl, M. S. Wolfe, M. J. Rowan and D. J. Selkoe: Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature, 416, 535-9 (2002) (Pubitemid 34288854)
41. A. Caccamo, S. Majumder, A. Richardson, R. Strong and S. Oddo: Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem, 285, 13107-20 (2010)
42. L. M. Billings, S. Oddo, K. N. Green, J. L. McGaugh and F. M. LaFerla: Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron, 45, 675-88 (2005) (Pubitemid 40320703)
43. S. Oddo, A. Caccamo, D. Cheng, B. Jouleh, R. Torp and F. M. LaFerla: Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice. J Neurochem, 102, 1053-63 (2007) (Pubitemid 47174220)
44. S. Oddo, A. Caccamo, J. D. Shepherd, M. P. Murphy, T. E. Golde, R. Kayed, R. Metherate, M. P. Mattson, Y. Akbari and F. M. LaFerla: Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron, 39, 409-21 (2003) (Pubitemid 36937044)
45. S. Oddo, A. Caccamo, B. Tseng, D. Cheng, V. Vasilevko, D. H. Cribbs and F. M. LaFerla: Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. J Neurosci, 28, 12163-75 (2008)
46. S. Oddo, A. Caccamo, M. Kitazawa, B. P. Tseng and F. M. LaFerla: Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging, 24, 1063-70 (2003) (Pubitemid 37487883)
47. S. Oddo, A. Caccamo, D. Cheng and F. M. LaFerla: Genetically altering Abeta distribution from the brain to the vasculature ameliorates tau pathology. Brain Pathol, 19, 421-30 (2009)
48. S. Oddo, A. Caccamo, L. Tran, M. P. Lambert, C. G. Glabe, W. L. Klein and F. M. LaFerla: Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem, 281, 1599-604 (2006)
49. A. Caccamo, M. A. Maldonado, S. Majumder, D. X. Medina, W. Holbein, A. Magri and S. Oddo: Naturally secreted amyloid-{beta} increases mTOR activity via a PRAS40-mediated mechanism. J Biol Chem (2011)
50. Y. Sancak, C. C. Thoreen, T. R. Peterson, R. A. Lindquist, S. A. Kang, E. Spooner, S. A. Carr and D. M. Sabatini: PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell, 25, 903-15 (2007) (Pubitemid 46436534)
51. L. Wang, T. E. Harris, R. A. Roth and J. C. Lawrence, Jr.: PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem, 282, 20036-44 (2007) (Pubitemid 47100127)
52. E. B. Nascimento, M. Snel, B. Guigas, G. C. van der Zon, J. Kriek, J. A. Maassen, I. M. Jazet, M. Diamant and D. M. Ouwens: Phosphorylation of PRAS40 on Thr246 by PKB/AKT facilitates efficient phosphorylation of Ser183 by mTORC1. Cell Signal, 22, 961-7 (2010)
53. A. Casadio, K. C. Martin, M. Giustetto, H. Zhu, M. Chen, D. Bartsch, C. H. Bailey and E. R. Kandel: A transient, neuron-wide form of CREB-mediated long-term facilitation can be stabilized at specific synapses by local protein synthesis. Cell, 99, 221-37 (1999) (Pubitemid 29491788)
54. D. Ehninger, S. Han, C. Shilyansky, Y. Zhou, W. Li, D. J. Kwiatkowski, V. Ramesh and A. J. Silva: Reversal of learning deficits in a Tsc2+/-mouse model of tuberous sclerosis. Nat Med, 14, 843-8 (2008)
55. E. Puighermanal, G. Marsicano, A. Busquets-Garcia, B. Lutz, R. Maldonado and A. Ozaita: Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nat Neurosci, 12, 1152-8 (2009)
56. W. Tischmeyer, H. Schicknick, M. Kraus, C. I. Seidenbecher, S. Staak, H. Scheich and E. D. Gundelfinger: Rapamycin-sensitive signalling in long-term consolidation of auditory cortex-dependent memory. Eur J Neurosci, 18, 942-50 (2003) (Pubitemid 37059704)
57. P. K. Dash, S. A. Orsi and A. N. Moore: Spatial memory formation and memory-enhancing effect of glucose involves activation of the tuberous sclerosis complex-Mammalian target of rapamycin pathway. J Neurosci, 26, 8048-56 (2006) (Pubitemid 44315129)
58. R. G. Parsons, G. M. Gafford and F. J. Helmstetter: Translational control via the mammalian target of rapamycin pathway is critical for the formation and stability of long-term fear memory in amygdala neurons. J Neurosci, 26, 12977-83 (2006) (Pubitemid 44954616)
59. O. Steward and E. M. Schuman: Compartmentalized synthesis and degradation of proteins in neurons. Neuron, 40, 347-59 (2003) (Pubitemid 37244100)
60. N. Takei, N. Inamura, M. Kawamura, H. Namba, K. Hara, K. Yonezawa and H. Nawa: Brain-derived neurotrophic factor induces mammalian target of rapamycin-dependent local activation of translation machinery and protein synthesis in neuronal dendrites. J Neurosci, 24, 9760-9 (2004) (Pubitemid 39463557)
61. S. J. Tang, G. Reis, H. Kang, A. C. Gingras, N. Sonenberg and E. M. Schuman: A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc Natl Acad Sci U S A, 99, 467-72 (2002) (Pubitemid 34060384)
62. R. Cao, A. Li and H. Y. Cho: mTOR signaling in epileptogenesis: too much of a good thing? J Neurosci, 29, 12372-3 (2009)
63. K. Inoki, M. N. Corradetti and K. L. Guan: Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet, 37, 19-24 (2005) (Pubitemid 40070934)
64. L. H. Zeng, N. R. Rensing and M. Wong: The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci, 29, 6964-72 (2009)
65. T. F. Cloughesy, K. Yoshimoto, P. Nghiemphu, K. Brown, J. Dang, S. Zhu, T. Hsueh, Y. Chen, W. Wang, D. Youngkin, L. Liau, N. Martin, D. Becker, M. Bergsneider, A. Lai, R. Green, T. Oglesby, M. Koleto, J. Trent, S. Horvath, P. S. Mischel, I. K. Mellinghoff and C. L. Sawyers: Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med, 5, e8 (2008)
66. S. Huang, M. A. Bjornsti and P. J. Houghton: Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther, 2, 222-32 (2003)
67. C. H. Kwon, X. Zhu, J. Zhang and S. J. Baker: mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc Natl Acad Sci U S A, 100, 12923-8 (2003) (Pubitemid 37340001)
68. N. Serkova, W. Jacobsen, C. U. Niemann, L. Litt, L. Z. Benet, D. Leibfritz and U. Christians: Sirolimus, but not the structurally related RAD (everolimus), enhances the negative effects of cyclosporine on mitochondrial metabolism in the rat brain. Br J Pharmacol, 133, 875-85 (2001) (Pubitemid 32751797)
69. J. G. Supko and L. Malspeis: Dose-dependent pharmacokinetics of rapamycin-28-N, N-dimethylglycinate in the mouse. Cancer Chemother Pharmacol, 33, 325-30 (1994) (Pubitemid 24033058)
70. P. Spilman, N. Podlutskaya, M. J. Hart, J. Debnath, O. Gorostiza, D. Bredesen, A. Richardson, R. Strong and V. Galvan: Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One, 5, e9979 (2010)
71. D. Ehninger, P. J. de Vries and A. J. Silva: From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis. J Intellect Disabil Res, 53, 838-51 (2009)
72. C. Malagelada, Z. H. Jin, V. Jackson-Lewis, S. Przedborski and L. A. Greene: Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci, 30, 1166-75 (2010)
73. A. Y. Choo and J. Blenis: Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy. Cell Cycle, 8, 567-72 (2009)
74. C. C. Thoreen, S. A. Kang, J. W. Chang, Q. Liu, J. Zhang, Y. Gao, L. J. Reichling, T. Sim, D. M. Sabatini and N. S. Gray: An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem, 284, 8023-32 (2009)
75. C. C. Thoreen and D. M. Sabatini: Rapamycin inhibits mTORC1, but not completely. Autophagy, 5, 725-6 (2009)
76. A. Y. Choo, S. O. Yoon, S. G. Kim, P. P. Roux and J. Blenis: Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci U S A, 105, 17414-9 (2008)
77. B. Ruan, K. Pong, F. Jow, M. Bowlby, R. A. Crozier, D. Liu, S. Liang, Y. Chen, M. L. Mercado, X. Feng, F. Bennett, D. von Schack, L. McDonald, M. M. Zaleska, A. Wood, P. H. Reinhart, R. L. Magolda, J. Skotnicki, M. N. Pangalos, F. E. Koehn, G. T. Carter, M. Abou-Gharbia and E. I. Graziani: Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities. Proc Natl Acad Sci U S A, 105, 33-8 (2008)
78. T. Morita and K. Sobue: Specification of neuronal polarity regulated by local translation of CRMP2 and Tau via the mTOR-p70S6K pathway. J Biol Chem, 284, 27734-45 (2009)
79. V. Meske, F. Albert and T. G. Ohm: Coupling of mammalian target of rapamycin with phosphoinositide 3-kinase signaling pathway regulates protein phosphatase 2Aand glycogen synthase kinase-3-dependent phosphorylation of Tau. J Biol Chem, 283, 100-9 (2008)
80. V. Janssens and J. Goris: Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J, 353, 417-39 (2001) (Pubitemid 32158309)
81. K. Iqbal, F. Liu, C. X. Gong, C. Alonso Adel and I. Grundke-Iqbal: Mechanisms of tau-induced neurodegeneration. Acta Neuropathol, 118, 53-69 (2009)
82. R. J. Dowling, M. Zakikhani, I. G. Fantus, M. Pollak and N. Sonenberg: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res, 67, 10804-12 (2007) (Pubitemid 350145909)
83. A. Vazquez-Martin, C. Oliveras-Ferraros and J. A. Menendez: The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle, 8, 88-96 (2009)
84. E. Kickstein, S. Krauss, P. Thornhill, D. Rutschow, R. Zeller, J. Sharkey, R. Williamson, M. Fuchs, A. Kohler, H. Glossmann, R. Schneider, C. Sutherland and S. Schweiger: Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci U S A (2010)
85. H. G. Lee, G. Casadesus, X. Zhu, R. J. Castellani, A. McShea, G. Perry, R. B. Petersen, V. Bajic and M. A. Smith: Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. Neurochem Int, 54, 84-8 (2009)
86. V. Khurana, Y. Lu, M. L. Steinhilb, S. Oldham, J. M. Shulman and M. B. Feany: TOR-mediated cell-cycle activation causes neurodegeneration in a Drosophila tauopathy model. Curr Biol, 16, 230-41 (2006) (Pubitemid 43190222)
87. C. W. Wittmann, M. F. Wszolek, J. M. Shulman, P. M. Salvaterra, J. Lewis, M. Hutton and M. B. Feany: Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science, 293, 711-4 (2001) (Pubitemid 32728676)
88. K. R. Brunden, J. Q. Trojanowski and V. M. Lee: Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies. Nat Rev Drug Discov, 8, 783-93 (2009)
89. A. M. Cuervo: Autophagy: many paths to the same end. Mol Cell Biochem, 263, 55-72 (2004) (Pubitemid 39256145)
90. D. J. Klionsky and S. D. Emr: Autophagy as a regulated pathway of cellular degradation. Science, 290, 1717-21 (2000) (Pubitemid 32004796)
91. C. H. Jung, C. B. Jun, S. H. Ro, Y. M. Kim, N. M. Otto, J. Cao, M. Kundu and D. H. Kim: ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol Biol Cell, 20, 1992-2003 (2009)
92. A. E. Majeski and J. F. Dice: Mechanisms of chaperone-mediated autophagy. Int J Biochem Cell Biol, 36, 2435-44 (2004) (Pubitemid 39119757)
93. A. M. Cuervo, E. Bergamini, U. T. Brunk, W. Droge, M. Ffrench and A. Terman: Autophagy and aging: the importance of maintaining "clean" cells. Autophagy, 1, 131-40 (2005)
94. Y. Kabeya, N. Mizushima, T. Ueno, A. Yamamoto, T. Kirisako, T. Noda, E. Kominami, Y. Ohsumi and T. Yoshimori: LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. Embo J, 19, 5720-8 (2000)
95. I. Tanida, N. Minematsu-Ikeguchi, T. Ueno and E. Kominami: Lysosomal turnover, but not a cellular level, of endogenous LC3 is a marker for autophagy. Autophagy, 1, 84-91 (2005)
96. S. Diaz-Troya, M. E. Perez-Perez, F. J. Florencio and J. L. Crespo: The role of TOR in autophagy regulation from yeast to plants and mammals. Autophagy, 4, 851-65 (2008)
97. B. A. McCray and J. P. Taylor: The role of autophagy in age-related neurodegeneration. Neurosignals, 16, 75-84 (2008) (Pubitemid 350308323)
98. N. B. Nedelsky, P. K. Todd and J. P. Taylor: Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection. Biochim Biophys Acta, 1782, 691-9 (2008)
99. D. C. Rubinsztein: The roles of intracellular proteindegradation pathways in neurodegeneration. Nature, 443, 780-6 (2006) (Pubitemid 44622682)
100. S. Oddo: The ubiquitin-proteasome system in Alzheimer's disease. J Cell Mol Med, 12, 363-73 (2008) (Pubitemid 351555121)
101. X. Li, H. Li and X. J. Li: Intracellular degradation of misfolded proteins in polyglutamine neurodegenerative diseases. Brain Res Rev, 59, 245-52 (2008)
102. A. Caccamo, S. Majumder, J. J. Deng, Y. Bai, F. B. Thornton and S. Oddo: Rapamycin rescues TDP-43 mislocalization and the associated low molecular weight neurofilament instability. J Biol Chem (2009)
103. M. Martinez-Vicente and A. M. Cuervo: Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol, 6, 352-61 (2007) (Pubitemid 46367949)
104. T. Hara, K. Nakamura, M. Matsui, A. Yamamoto, Y. Nakahara, R. Suzuki-Migishima, M. Yokoyama, K. Mishima, I. Saito, H. Okano and N. Mizushima: Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature, 441, 885-9 (2006)
105. M. Komatsu, S. Waguri, T. Chiba, S. Murata, J. Iwata, I. Tanida, T. Ueno, M. Koike, Y. Uchiyama, E. Kominami and K. Tanaka: Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature, 441, 880-4 (2006)
106. M. Komatsu, Q. J. Wang, G. R. Holstein, V. L. Friedrich, Jr., J. Iwata, E. Kominami, B. T. Chait, K. Tanaka and Z. Yue: Essential role for autophagy protein Atg7 in the maintenance of axonal homeostasis and the prevention of axonal degeneration. Proc Natl Acad Sci U S A, 104, 14489-94 (2007) (Pubitemid 350010651)
107. Z. Berger, B. Ravikumar, F. M. Menzies, L. G. Oroz, B. R. Underwood, M. N. Pangalos, I. Schmitt, U. Wullner, B. O. Evert, C. J. O'Kane and D. C. Rubinsztein: Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum Mol Genet, 15, 433-42 (2006) (Pubitemid 43159895)
108. J. Shao and M. I. Diamond: Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum Mol Genet, 16 Spec No. 2, R115-23 (2007)
109. M. Ouellet, V. Emond, C. T. Chen, C. Julien, F. Bourasset, S. Oddo, F. LaFerla, R. P. Bazinet and F. Calon: Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood-brain barrier: An in situ cerebral perfusion study. Neurochem Int, 55, 476-82 (2009)
110. B. Ravikumar, C. Vacher, Z. Berger, J. E. Davies, S. Luo, L. G. Oroz, F. Scaravilli, D. F. Easton, R. Duden, C. J. O'Kane and D. C. Rubinsztein: Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet, 36, 585-95 (2004) (Pubitemid 38715985)
111. F. Fornai, P. Longone, L. Cafaro, O. Kastsiuchenka, M. Ferrucci, M. L. Manca, G. Lazzeri, A. Spalloni, N. Bellio, P. Lenzi, N. Modugno, G. Siciliano, C. Isidoro, L. Murri, S. Ruggieri and A. Paparelli: Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A, 105, 2052-7 (2008) (Pubitemid 351439463)
112. U. B. Pandey, Z. Nie, Y. Batlevi, B. A. McCray, G. P. Ritson, N. B. Nedelsky, S. L. Schwartz, N. A. DiProspero, M. A. Knight, O. Schuldiner, R. Padmanabhan, M. Hild, D. L. Berry, D. Garza, C. C. Hubbert, T. P. Yao, E. H. Baehrecke and J. P. Taylor: HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature, 447, 859-63 (2007) (Pubitemid 46920134)
113. W. H. Yu, B. Dorado, H. Y. Figueroa, L. Wang, E. Planel, M. R. Cookson, L. N. Clark and K. E. Duff: Metabolic activity determines efficacy of macroautophagic clearance of pathological oligomeric alpha-synuclein. Am J Pathol, 175, 736-47 (2009)
114. B. Boland, A. Kumar, S. Lee, F. M. Platt, J. Wegiel, W. H. Yu and R. A. Nixon: Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease. J Neurosci, 28, 6926-37 (2008)
115. W. H. Yu, A. M. Cuervo, A. Kumar, C. M. Peterhoff, S. D. Schmidt, J. H. Lee, P. S. Mohan, M. Mercken, M. R. Farmery, L. O. Tjernberg, Y. Jiang, K. Duff, Y. Uchiyama, J. Naslund, P. M. Mathews, A. M. Cataldo and R. A. Nixon: Macroautophagy-a novel Beta-amyloid peptidegenerating pathway activated in Alzheimer's disease. J Cell Biol, 171, 87-98 (2005) (Pubitemid 41434604)
116. S. Y. Hung, W. P. Huang, H. C. Liou and W. M. Fu: Autophagy protects neuron from Abeta-induced cytotoxicity. Autophagy, 5, 502-10 (2009)
117. D. Ling and P. M. Salvaterra: A central role for autophagy in Alzheimer-type neurodegeneration. Autophagy, 5, 738-40 (2009)
118. D. Ling, H. J. Song, D. Garza, T. P. Neufeld and P. M. Salvaterra: Abeta42-induced neurodegeneration via an agedependent autophagic-lysosomal injury in Drosophila. PLoS One, 4, e4201 (2009)
119. F. Pickford, E. Masliah, M. Britschgi, K. Lucin, R. Narasimhan, P. A. Jaeger, S. Small, B. Spencer, E. Rockenstein, B. Levine and T. Wyss-Coray: The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest, 118, 2190-9 (2008) (Pubitemid 351872337)
120. P. J. Khandelwal, A. M. Herman, H. S. Hoe, G. W. Rebeck and C. E. Moussa: Parkin mediates beclindependent autophagic clearance of defective mitochondria and ubiquitinated A{beta} in AD models. Hum Mol Genet (2011)
121. Y. Tian, V. Bustos, M. Flajolet and P. Greengard: A small-molecule enhancer of autophagy decreases levels of A{beta} and APP-CTF via Atg5-dependent autophagy pathway. Faseb J (2011)
122. D. S. Yang, P. Stavrides, P. S. Mohan, S. Kaushik, A. Kumar, M. Ohno, S. D. Schmidt, D. Wesson, U. Bandyopadhyay, Y. Jiang, M. Pawlik, C. M. Peterhoff, A. J. Yang, D. A. Wilson, P. St George-Hyslop, D. Westaway, P. M. Mathews, E. Levy, A. M. Cuervo and R. A. Nixon: Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. Brain, 134, 258-77 (2011)